OSE identifies myeloid checkpoint target; plus a call from NCI for COVID-19 test proposals, Sinopharm vaccine data and more

BioCentury’s roundup of preclinical news

mAbs against new myeloid checkpoint
OSE Immunotherapeutics S.A. (Euronext:OSE) has identified CLEC1A, a carbohydrate-binding protein, as a tumor myeloid checkpoint target, and has generated mAbs that prevent CLEC1A from binding its ligand on tumor cells. The company showed the mAbs increased macrophage and dendritic cell activity against tumor cells. In mice modeling colon cancer, CLEC1A

Read the full 549 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE